Abrogation of Mitochondrial Cytochrome c Release and Caspase-3 Activation in Acquired Multidrug Resistance
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Acquired multidrug resistance to anti-cancer agents has been associated with overexpression of the P-glycoprotein and other members of the ATP-binding cassette superfamily. The present studies demonstrate that SCC-25 cells selected for resistance to the alkylating agent cisplatin (CDDP) overexpress the anti-apoptotic Bcl-xL protein. In contrast to parental cells, the SCC-25/CDDP-resistant variant failed to exhibit activation of caspase-3, cleavage of protein kinase C delta, and other characteristics of apoptosis in response to CDDP. Similar results were obtained when SCC-25/CDDP cells were exposed to the structurally and functionally unrelated antimetabolite 1-beta-D-arabinofuranosyl-cytosine (ara-C). Other cells selected for resistance to doxorubicin or vincristine also exhibited overexpression of Bcl-xL and failed to respond to CDDP and ara-C with activation of caspase-3. The results further demonstrate that multidrug-resistant cells exhibit a block in the release of mitochondrial cytochrome c into the cytosol and that this effect is dependent on overexpression of Bcl-xL. The demonstration that lysates from the resistant cells respond to the addition of cytochrome c with activation of caspase-3 confirms that the block in apoptosis is because of inhibition of mitochondrial cytochrome c release. These findings demonstrate that cells respond to diverse classes of anti-cancer drugs with overexpression of Bcl-xL and that this response represents another mechanism of acquired multidrug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415
Cited by
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
“Increased levels of cytochrome c are observed in the cytoplasm of cisplatin-treated cells, indicating that cytochrome c release is required for cisplatin-induced apoptosi”
BackgroundIs Cisplatin-Induced Cell Death Always Produced by Apoptosis?
Gonzalez, V. M., Fuertes, M. A., Alonso, C., & Perez, J. M. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09232-0 · Cited by 578
Deng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M., & Letai, A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 513
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Nowak, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206373200 · Cited by 265
Wartenberg, M., Gronczynska, S., Bekhite, M. M., Saric, T., Niedermeier, W., Hescheler, J., & Sauer, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20596 · Cited by 82
Metadata
- Authors
- Kojima, H., Endo, K., Moriyama, H., Tanaka, Y., Alnemri, E. S., Slapak, C. A., Teicher, B., Kufe, D., & Datta, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1998-07
- Volume
- 273
- Issue
- 27
- Pages
- 16647-16650
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2085301972
- Cited by
- 131
- References
- 3
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.